LL-K9-3

N/A

Report date: 2022/08/05 12:04:51
NME

Base Information

Drug NameLL-K9-3
Drug Alias NameLL-K9-3
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsAndrogen Receptor antagonistsMyc proto-oncogene protein inhibitors
TargetsCyclin-dependent kinase 9Androgen ReceptorMyc proto-oncogene protein
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A